Cjc-1295 Dac Research Peptide

Direct Overview: CJC-1295 DAC in Laboratory Settings

The cjc-1295 dac research peptide is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered with a reactive maleimido-propionic acid moiety. In biochemical assays, this modification allows the peptide to form a covalent bond with endogenously circulating serum albumin, exponentially extending its plasma half-life compared to native GHRH(1-29).

Designed strictly for in vitro experiments and animal model evaluation, researchers utilize CJC-1295 DAC to examine long-duration somatotroph stimulation, receptor downregulation mechanics, and secondary signaling pathways related to cellular repair and metabolic regulation. By establishing stable baseline ligand concentrations, the compound eliminates the rapid plasma degradation typically observed with unmodified secretagogues.

Molecular Structure and the Drug Affinity Complex (DAC) Technology

At the structural level, CJC-1295 DAC is derived from the core sequence of GHRH(1-29), known as Sermorelin, with four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27). These specific side-chain modifications confer enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV), a primary endopeptidase responsible for cleaving native GHRH peptides between positions 2 and 3.

The critical differentiator of this compound is the addition of a bioconjugate linker attached to the C-terminal lysine residue: tetra-substituted modified GRF(1-29) linked to a maleimide linker containing a propionic acid reactive group. When introduced into biological matrices containing albumin, the maleimide group reacts specifically with the free thiol residue on Cys34 of albumin. This spontaneous conjugation hides sensitive cleavage sites from circulating proteases and delays renal filtration, converting a peptide with a native half-life of minutes into a target ligand capable of sustained signaling over several days in animal models.

Investigators interested in mapping GHRH receptor binding affinity and metabolic transport often utilize our comprehensive research hub to evaluate data regarding bioconjugate peptide chemistry and stability kinetics.

Mechanism of Action: Secretagogue Activation at the GHRH Receptor

The fundamental mechanism of the cjc-1295 dac research peptide revolves around selective binding to the growth hormone-releasing hormone receptor (GHRH-R), a class B G-protein coupled receptor situated on anterior pituitary somatotroph cells. Ligand binding activates the Gs alpha subunit, which subsequently stimulates membrane-bound adenylyl cyclase.

This enzymatic activation converts intracellular adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), triggering downstream activation of protein kinase A (PKA). The resulting signaling cascade drives calcium influx through voltage-gated channels, culminating in the gene transcription and exocytosis of growth hormone (GH) stored in somatotroph granules.

Preclinical studies suggest that unlike native pulsed GHRH signaling, the sustained presence of CJC-1295 DAC promotes continuous baseline elevation of GH release while maintaining natural pulsatile secretory spikes driven by endogenous somatostatin tone. This sustained GH output acts upon hepatic receptors to stimulate the transcription and release of insulin-like growth factor 1 (IGF-1), an essential mediator in tissue turnover, cell proliferation, and nitrogen retention assays.

Preclinical Literature & Downstream Signaling Pathways

In vitro data and rodent research models demonstrate that extended GHRH receptor signaling via CJC-1295 DAC alters gene expression profiles related to musculoskeletal structural remodeling and lipid oxidation. By elevating serum IGF-1 levels in a dose-dependent manner without causing persistent somatotroph desensitization at low physiological ranges, the peptide provides a controlled environment for examining anabolic tissue pathways.

In cell culture assays, exposure to sustained GHRH agonists demonstrates upregulation of collagen mRNA transcription, enhanced fibroblast proliferation, and accelerated cell migration across scratch-wound assays. Furthermore, animal studies assessing myoblast maturation indicate that chronic IGF-1 receptor activation mediated by continuous GHRH secretagogues enhances satellite cell incorporation into existing muscle fibers.

In research involving systemic metabolism, rodents exposed to long-acting GHRH analogs display altered adipocyte gene expression, characterized by increased expression of hormone-sensitive lipase (HSL) and reduced lipogenesis. These preclinical findings make the compound a frequent target of study for tissue regeneration and metabolic efficiency models.

Comparative Analysis: CJC-1295 DAC vs. Non-DAC and Related Secretagogues

When designing peptide protocols targeting the somatotropic axis, researchers must evaluate how structural modifications alter clearance profiles and receptor interaction dynamics. The cjc-1295 dac research peptide belongs to a broad class of secretagogues, but its bioconjugate linker sets it apart from non-conjugated variants and ghrelin receptor agonists.

For example, CJC-1295 No DAC (also known as modified GRF 1-29) shares the exact same four DPP-IV resistant amino acid substitutions but lacks the reactive maleimido-propionic acid linker. Consequently, CJC-1295 No DAC exhibits a half-life of approximately 30 minutes in plasma, requiring frequent exposure models to maintain elevated signaling, whereas CJC-1295 DAC maintains receptor engagement over 6 to 8 days in rodent studies.

When compared to direct ghrelin receptor (GHSR-1a) agonists such as Ipamorelin or earlier GHRH fragment analogs like Sermorelin, CJC-1295 DAC acts strictly through the native GHRH receptor pathway. While Ipamorelin mimics ghrelin to stimulate GH release without raising cortisol or prolactin, CJC-1295 DAC acts synergistically along the hypothalamic-pituitary axis. Laboratories examining dual-receptor co-stimulation often pair GHRH analogs with selective GHRPs to evaluate synergistic somatotroph release profiles. For high-volume research laboratories seeking bulk quantities for comparative studies, PX1 Research provides specialized procurement options through our wholesale program.

Handling, Reconstitution, and Storage Parameters for In Vitro Protocols

To preserve the structural integrity of the cjc-1295 dac research peptide and prevent premature hydrolysis of the reactive maleimide linker, strict reconstituted handling and storage protocols must be adhered to in laboratory environments.

Lyophilized CJC-1295 DAC should be stored upon receipt at -20°C or -80°C for long-term stability. The dry peptide cake remains stable for up to 24 months under desiccated, sub-zero conditions. Prior to reconstitution, vials should be allowed to equilibrate to room temperature to prevent condensation accumulation inside the container, which can accelerate hydrolytic degradation.

Reconstitution should be executed using sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade sterile saline depending on downstream assay compatibility. The diluent should be introduced gently along the glass wall of the vial rather than sprayed directly onto the lyophilized powder. Swirl the vial gently until full dissolution occurs; mechanical vortexing or vigorous shaking must be strictly avoided, as shear stress can cause peptide denaturation or aggregation. Reconstituted solutions should be stored at 2°C to 8°C and utilized within 14 to 28 days, or aliquoted and refrozen at -80°C to prevent repeated freeze-thaw cycles.

Analytical Quality Standards and Verification Testing

The utility of preclinical research data relies entirely upon the chemical purity and structural identity of the target peptide. Low-purity compounds, residual trifluoroacetic acid (TFA), or bacterial endotoxin contamination can introduce confounding variable responses in cell culture and animal models.

PX1 Research subjects every production lot of CJC-1295 DAC to a comprehensive battery of analytical testing performed by independent third-party laboratories. Purity is characterized using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring that the active peptide content consistently exceeds 99.0% purity with minimal sequence truncated impurities.

Molecular weight identity is definitively confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), matching the theoretical mass of the 30-amino acid conjugated structure. Furthermore, biological compatibility is verified via Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below <0.01 EU/mg, protecting cellular assays from non-specific inflammatory responses. Investigators can inspect lot-specific documentation directly via our verified all peptides catalog.

Sourcing Criteria for Academic and Industrial Investigators

When selecting a supplier for the cjc-1295 dac research peptide, research institutions must demand verifiable quality documentation over marketing claims. High-throughput research environments require consistent lot-to-lot repeatability, guaranteed identity confirmation, and fully traceable supply chains.

PX1 Research manufactures all compounds within state-of-the-art, US-based GMP-compliant facilities. Every batch undergoes rigorous quality control within an ISO 17025 accredited analytical facility, providing transparent Certificate of Analysis (COA) documents linked directly to specific lot numbers.

To prevent project delays, PX1 Research operates dual distribution centers in California and Arizona, offering same-day shipping for orders placed Monday through Friday prior to cutoff times. This infrastructure guarantees that laboratories receive verified, high-purity compounds rapidly, backed by technical customer support dedicated exclusively to institutional researchers.